Buscar
15/11/2025
Effects of radiofrequency electromagnetic fields on cognitive function in elderly subjects (60+years)-Results of an experimental randomized sham controlled double-blind cross-over study in women and in men
Sauter, C, Dorn, H, Bueno-Lopez, A, Eggert, T, Schmid, G, Danker-Hopfe, H. Effects of radiofrequency electromagnetic fields on cognitive function in elderly subjects (60+years)-Results of an experimental randomized sham controlled double-blind cross-over study in women and in men. ENVIRONMENTAL RESEARCH. 2025; 285DOI:10.1016/j.envres.2025.122479. PMID:40744201. IF:7.700(Q1/1D).
02/09/2025
An overview of the rivastigmine 13.3 mg/24h transdermal patch as a treatment option for Alzheimer's disease
Fortea, J, Ferrer-Picón, E. An overview of the rivastigmine 13.3 mg/24h transdermal patch as a treatment option for Alzheimer's disease. Expert Review of Neurotherapeutics. 2025; 25(9)DOI:10.1080/14737175.2025.2527211. PMID:40600688. IF:3.400(Q2/3D).
01/08/2025
Impaired cerebrospinal fluid lipoprotein-mediated cholesterol transport in Alzheimer's disease
Querol, CB, Canyelles, M, Santos, D, Martínez, J, Mercer, A, Zhao, Q, Rotllan, N, Núñez, E, Vázquez, J, Maspoch, D, Cano-Sarabia, M, Carmona-Iragui, M, Sirisi, S, Lleó, A, Fortea, J, Alcolea, D, Blanco-Vaca, F, Escolà-Gil, JC, Tondo, M. Impaired cerebrospinal fluid lipoprotein-mediated cholesterol transport in Alzheimer's disease. ATHEROSCLEROSIS. 2025; 407DOI:. PMID:. IF:5.700(Q1/1D).
22/07/2025
CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer's disease patients
Oosthoek, M, Vijverberg, EGB, Blujdea, ER, Veld, SGJGI, Avilés, MP, Zsadanyi, SE, Hok-A-Hin, YS, Visser, A, van der Flier, WM, Barkhof, F, del Campo, M, Schut, MC, Bejanin, A, Alcolea, D, Teunissen, CE, Vermunt, L. CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer's disease patients. Alzheimers Research & Therapy. 2025; 17(1)DOI:10.1186/s13195-025-01799-3. PMID:40696469. IF:7.600(Q1/1D).